

WHAT IS CLAIMED IS:

1. A polypeptide composition comprising a variant human IL-2 protein wherein said variant IL-2 protein comprises amino acid substitution(s) as compared to SEQ ID NO:2 selected from the group of T3A/D20N/T37R and T3A/D20N/N71K.
2. A polypeptide composition according to claim 1 wherein said variant IL-2 protein further comprises a C125S variant.
3. A polypeptide composition according to claim 1 wherein said IL-2 variant further comprises a C125A variant.
4. A polypeptide composition according to claim 1, 2 or 3 wherein said polypeptide composition is a homodimeric protein complex wherein each protein monomer comprises said variant IL-2 protein covalently attached to an Fc domain.
5. A polypeptide composition according to claim 4 wherein each of said Fc domains is a variant Fc domain.
6. A polypeptide composition according to claim 1, 2 or 3 wherein said polypeptide composition is a heterodimeric protein complex comprising a first protein monomer comprising said variant IL-2 protein is covalently attached to a first variant Fc domain and a second protein monomer comprising a second variant Fc domain.
7. A polypeptide composition according to claim 5 or 6 wherein said variant Fc domains are variant human IgG1 Fc domains comprising the amino acid substitutions M428L/N434S.
8. A polypeptide composition according to claim 5 or 6 wherein said variant Fc domains are variant human IgG1 Fc domains comprising the amino acid substitutions E233P/L234V/L235A/G236del/S267K.
9. A polypeptide composition according to claim 6, 7 or 8 wherein said first and second variant Fc domains comprise a set of heterodimerization variants selected from the group consisting of those depicted in Figure 2.

10. A polypeptide composition according to claim 9 wherein said set of heterodimerization variants selected from the group consisting of L368D/K370S : S364K/E357Q; L368D/K370S : S364K; L368E/K370S : S364K; T411E/K360E/Q362E : D401K; and T366S/L368A/Y407V : T366W.
11. A polypeptide composition according to claim 6, 7, 8, 9 or 10 wherein one of said variant Fc domains comprise a set of pI variants selected from the group consisting of those depicted in Figure 3.
12. A polypeptide composition according to claim 11 wherein said pI variant set is A295E/N384D/Q418/N421D.
13. A polypeptide composition according to 6 wherein said polypeptide composition is selected from the group consisting of XENP27564 (SEQ ID NOs:297 and 298), XENP27563 (SEQ ID NOs:295 and 296), XENP26105 (SEQ ID NOs:245 and 246), and XENP26109 (SEQ ID NOs:249 and 250).
14. A nucleic acid composition comprising a nucleic acid encoding the variant human IL-2 protein according to claim 1.
15. A nucleic acid composition comprising:
- a) a first nucleic acid encoding said first protein monomer of any of claims 6 to 13;
- and
- b) a second nucleic acid encoding said second protein monomer of any of claims 6 to 13, respectively.
16. An expression vector composition comprising:
- a) a first expression vector comprising said first nucleic acid of claim 15; and
 - b) a second expression vector comprising said second nucleic acid of claim 15.
17. A host cell comprising the expression vector composition according to claim 16.
18. A method of making a polypeptide composition comprising culturing the host cell of claim 1 under conditions wherein said composition is produced and recovering said composition.